Table 1.
Study population characteristics
| Characteristic | Overall n = 321 |
Group TND n = 113 |
Group RV n = 113 |
Group LLV n = 95 |
p a |
|---|---|---|---|---|---|
| Age, y | 53 [47–58] | 52 [45–57] | 54 [49–62] | 53 [47–57] | |
| Male (%) | 217 (67) | 75 (66) | 78 (69) | 64 (57) | |
| Race/Ethnicity white/latino/other (%) | 316 (98.5) | 113 (100) | 111 (98.2) | 92 (97) | |
| Black (%) | 5 (1.5) | 0 | 2.0 (1.8) | 3.0 (3.0) | |
| CD4 cells/mm3 | 601 [382–854] | 641 [523–888] | 565 [303–795] | 565 [356–925] | 0.017 |
| Nadir CD4 cells/mm3 | 222 [108–366] | 209 [112–362] | 243 [108–327] | 232 [107–409] | |
| HIV infection, y | 16 [10–22] | 16 [13–21] | 15 [8.0–20] | 18 [10–22] | |
| Duration of ART, y | 15 [9.0–18.5] | 15 [12–18] | 13 [6.0–18] | 18 [10–21] | |
| HCV coinfection, n (%) | 55 (17.1) | 14 (12.4) | 24 (21.2) | 17 (17.9) | |
| HBV coinfection, n (%) | 17 (5.3) | 6.0 (5.3) | 4.0 (3.5) | 7.0 (7.3) |
Data are median [interquartile range] unless otherwise stated
aKruskal-Wallis tests
Abbreviations: TND target not detected, RV residual viremia, LLV low level viremia, ART antiretroviral therapy, HCV hepatitis C virus, HBV hepatitis B virus